Article

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab

2025-06-09

Abstract excerpt

<title>Abstract</title> <p>We analyzed the pathways associated with therapeutic response in 19 patients (5 responders) enrolled in a Phase Ib trial (NCT02453620) diagnosed with advanced HER2-negative breast cancer and treated with the HDAC inhibitor entinostat, in combination with dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab. The analysis included gene expression and T-cell receptor (TCR) re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a2163719-dfed-5249-b1c4-26b77e6611d3
DOI: 10.21203/rs.3.rs-6580687/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumabDOI 10.21203/rs.3.rs-6580687/v1Read

Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2 <sup>+</sup> tumor immunitySemantic proximity Read

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancerSemantic proximity Read

Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast CancerSemantic proximity Read

TimiGP-Response: the pan-cancer immune landscape associated with response to immunotherapySemantic proximity Read

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscapeSemantic proximity Read

Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancerSemantic proximity Read

Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity Read

The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancerSemantic proximity Read

Immune cell networks uncover candidate biomarkers of cancer immunotherapy responseSemantic proximity Read

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.Semantic proximity Read

Drug repositioning for immunotherapy in breast cancer using single-cell and spatial transcriptomics analysisSemantic proximity Read

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity Read